Kenvue Business Summary

Kenvue Inc. (KVUE) operates as the world’s largest pure-play consumer health company, generating approximately $15 billion in annual revenue through the global sale of science-backed personal care and over-the-counter (OTC) products. The company’s business model is structured across three primary segments: Self Care, which includes dominant brands like Tylenol, Motrin, and Zyrtec; Skin Health & Beauty, featuring Neutrogena and Aveeno; and Essential Health, comprising Listerine, Band-Aid, and Johnson’s. As of early 2026, Kenvue is executing its "Our Vue Forward" strategic program to realize $350 million in annualized cost savings while navigating a definitive agreement to be acquired by Kimberly-Clark Corporation, a deal expected to close in the second half of 2026. Kenvue maintains a leading market position ahead of direct competitors such as Haleon, Procter & Gamble, Unilever, and Colgate-Palmolive, leveraging its massive retail footprint and 30%+ value share in key categories like mouthwash. The leadership team is headed by Chief Executive Officer Kirk Perry, who assumed the permanent role in November 2025 following his tenure as CEO of Circana and executive roles at Google and Procter & Gamble. The financial division is currently led by Chief Financial Officer Amit Banati, a veteran of Kellanova and P&G, who is slated to step down in May 2026. Other key executives include Chief Technology & Data Officer Michael Wondrasch and Chief Scientific Officer Caroline Tillett, PhD. The Board of Directors is chaired by Larry Merlo, the former CEO of CVS Health, and includes notable activist investor Jeffrey Smith, Managing Member of Starboard Value LP, who joined the board in 2025 following a cooperation agreement aimed at accelerating shareholder value and operational efficiency.